A Study to Assess Efficacy and Safety of Pembrolizumab With or Without MK- 2870 in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Conditions: Non Small Cell Lung Cancer Interventions: Biological: MK-2870; Biological: Pembrolizumab; Drug: Cisplatin; Drug: Pemetrexed; Drug: Gemcitabine; Drug: Carboplatin; Drug: Paclitaxel Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
MK-2870 Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Conditions: Non-small Cell Lung Cancer (NSCLC) Interventions: Biological: MK-2870; Drug: Pemetrexed; Drug: Carboplatin; Drug: Antihistamine; Drug: H2 Receptor Antagonist; Drug: Acetaminophen (or equivalent); Drug: Dexamethasone (or equivalent) Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g.'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
Conditions: Leptomeningeal Metastasis Interventions: Drug: Osimertinib; Drug: Pemetrexed Sponsors: Guangzhou Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
Conditions: Leptomeningeal Metastasis Interventions: Drug: Pemetrexed Sponsors: Guangzhou Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
Conditions: Non-Small-Cell Lung Cancer Interventions: Drug: PLB1004; Drug: Pemetrexed+ （carboplatin or Cisplatin）with or without Sintilimab Sponsors: Avistone Biotechnology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda ®(EU/US) in Participants With IV nqNSCLC
Conditions: Carcinoma, Non-Small-Cell Lung Interventions: Drug: BAT3306; Drug: EU-Keytruda ®; Drug: US-Keytruda®; Drug: Pemetrexed; Drug: Carboplatin Sponsors: Bio-Thera Solutions Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
Conditions: Non-small Cell Lung Cancer Interventions: Drug: Cadonilimab plus Pemetrexed and Anlotinib Sponsors: Guangzhou University of Traditional Chinese Medicine; Akeso Pharmaceuticals, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Interventions: Drug: Lazertinib+Pemetrexed+Carboplatin; Drug: Lazertinib Sponsors: Yonsei University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 20, 2024 Category: Research Source Type: clinical trials
A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer
Conditions: NSCLC Interventions: Drug: EIK1001; Biological: Pembrolizumab; Drug: Paclitaxel; Drug: Pemetrexed; Drug: Carboplatin Sponsors: Eikon Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Conditions: Non-Small Cell Lung Cancer Interventions: Drug: Livmoniplimab; Drug: Budigalimab; Drug: Pembrolizumab; Drug: Pemetrexed; Drug: Cisplatin; Drug: Carboplatin; Drug: Carboplatin Sponsors: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
Conditions: Metastatic Non-small Cell Lung Cancer Interventions: Biological: Pembrolizumab coformulated with hyaluronidase; Drug: Pemetrexed; Drug: Cisplatin; Drug: Carboplatin; Drug: Paclitaxel; Drug: Nab-paclitaxel; Biological: Pembrolizumab Sponsors: Merck Sharp& Dohme LLC Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
Conditions: Lung Cancer Interventions: Drug: Osimertinib; Drug: Cisplatin or Carboplatin; Pemetrexed or Paclitaxel; Drug: Radiation Sponsors: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Conditions: Nonsquamous Non-small Cell Lung Cancer Interventions: Combination Product: Vudalimab + Carboplatin + Pemetrexed; Combination Product: Pembrolizumab + Carboplatin + Pemetrexed Sponsors: Xencor, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2023 Category: Research Source Type: clinical trials
Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC
Conditions: Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer Interventions: Drug: RMC-6291; Drug: RMC-6236; Drug: Pembrolizumab; Drug: Cisplatin; Drug: Carboplatin; Drug: Pemetrexed Sponsors: Revolution Medicines, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-small Cell Lung Cancer That Can be Treated With Surgery.
Conditions: Resectable Non-small Cell Lung Cancer Interventions: Drug: Fianlimab; Drug: Cemiplimab; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Drug: Cisplatin; Drug: Placebo Sponsors: Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
